Dr. Gerald Zon (photo), a distinguished DNA scientist and Director of Business Development at TriLink BioTechnologies (trilinkbiotech.com) in San Diego, California, has just launched a biweekly blog that will post timely discussions of significant nucleic acid-related scientific content. This new blog promises to be of keen interest to many BioQuick readers and may be found at http://zon.trilinkbiotech.com. Dr. Zon’s inaugural article, posted on April 1, 2013, is entitled “60th Anniversary of the Discovery of DNA’s Double Helix Structure...Diamond Jubilee for the ‘Monarch of Molecules.’” The overall blog is called “Zone in with Zon--What’s Trending in Nucleic Acid Research.” A brief description of Dr. Zon’s broad experience is offered below. TriLink BioTechnologies is a company that offers cutting-edge services to researchers in the fields of gene therapy, nucleoside chemotherapy, and oligonucleotide therapy and diagnostics. TriLink specializes in the manufacture of modified nucleic acid products, including custom oligonucleotides, modified nucleoside triphosphates, CleanAmp™ PCR Products, RNA transcripts, phosphoramidites and other small molecules. Dr. Zon (Jerry) obtained his Ph.D. in chemistry from Princeton University in 1971. He subsequently developed automated synthesis of DNA analogs at the National Institutes of Health, and later at Applied Biosystems, Inc. (ABI). In 1992, he co-founded the ABI spin-off Lynx Therapeutics, an antisense company. He returned to ABI in 1999 to head up the DNA sequencing R&D group, and then he worked on novel methods for DNA sequencing as a Research Fellow at Life Technologies. In 2006, Dr. Zon was admitted as a Fellow of The Royal Society of Chemistry in the UK. At TriLink BioTechnologies since 2011, Dr. Zon has published over 260 papers and holds numerous patents.Login Or Register To Read Full Story